{"id":38490,"date":"2026-06-20T05:11:10","date_gmt":"2026-06-20T05:11:10","guid":{"rendered":"https:\/\/www.europesays.com\/france\/38490\/"},"modified":"2026-06-20T05:11:10","modified_gmt":"2026-06-20T05:11:10","slug":"press-release-sanofis-sarclisa-subcutaneous-formulation-approved-in-japan-for-patients-with-multiple-myeloma-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/france\/38490\/","title":{"rendered":"Press Release: Sanofi\u2019s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma"},"content":{"rendered":"

Sanofi\u2019s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma<\/p>\n

Approval based on multiple studies, including the pivotal IRAKLIA phase 3 study which demonstrated non-inferior efficacy and pharmacokinetics compared to Sarclisa IVSecond global approval for Sarclisa SC following the EUParis, June 19, 2026. The Ministry of Health, Labour and Welfare in Japan has granted approval for Sarclisa (isatuximab) subcutaneous (SC) formulation in combination with approved standard-of-care regimens for the treatment of multiple myeloma (MM). The approved indications for Sarclisa SC in Japan include in combination with pomalidomide and dexamethasone (Pd), or with carfilzomib for the treatment of relapsed or refractory MM (R\/R MM) and in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM).<\/p>\n

A regulatory submission for the CirCLIQ on-body injector (OBI), based on the enFuse platform and submitted by Enable Injections,\u00a0is under review in Japan. If approved, Sarclisa SC could become the first anticancer treatment to be administered via an OBI, and the first MM medicine in Japan to offer both manual SC injection and OBI administration.<\/p>\n

In recent years, new MM diagnoses have increased steadily in Japan, creating a need for new treatment approaches particularly in the front-line setting. MM is the third most common hematologic malignancy in Japan.<\/p>\n

“Today\u2019s approval of Sarclisa subcutaneous represents an important evolution in how we deliver care for multiple myeloma patients in Japan,\u201d\u00a0said Olivier Nataf,\u00a0Global Head of Oncology\u00a0at Sanofi.\u00a0“This new formulation significantly eases treatment burden and enhances convenience for patients compared to intravenous administration – with the potential to become Japan’s first anticancer therapy to be administered via an on-body injector.\u201d <\/p>\n

Get the latest news
\n

\n delivered to your inbox<\/p>\n

Sign up for The Manila Times newsletters<\/p>\n

By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service<\/a> and Privacy Policy<\/a>.<\/p>\n

The approval is based on results from the IRAKLIA phase 3 study in R\/R MM (clinical study identifier: NCT05405166<\/a>), which demonstrated non-inferiority of the SC formulation compared to IV, as well as supportive studies<\/a>. In addition to manual SC injection, these studies evaluated Sarclisa SC administered through an OBI, and were conducted using Enable Injections\u2019 enFuse hands-free OBI, an automated injector for subcutaneous delivery of Sarclisa.<\/p>\n

In the IRAKLIA study, Sarclisa SC administered via an OBI in combination with pomalidomide and dexamethasone (Pd) resulted in a 71.1% objective response rate (ORR), compared to 70.5% with Sarclisa IV-Pd, establishing non-inferiority (risk ratio: 1.008; 95% confidence interval: 0.903-1.126; p=0.0006), in adult patients with R\/R MM who had received at least one prior line of treatment.\u00a0The overall safety profile of Sarclisa SC-Pd observed in this study was consistent with the established safety profile of Sarclisa IV-Pd. While 25% of patients treated with Sarclisa IV-Pd experienced infusion\u00a0reactions, 1.5%\u00a0of patients treated with Sarclisa SC-Pd experienced those reactions.\u00a0No\u00a0new\u00a0safety\u00a0concerns\u00a0were\u00a0observed, except for low-grade local injection site reactions (ISRs)\u00a0that\u00a0occurred in 0.4% of OBI injections (n=19\/5,145 injections).\u00a0Nearly all\u00a0ISRs were grade 1, except for one episode of grade 2.<\/p>\n

The most common grade \u22653 non hematologic\u00a0adverse events were pneumonia (14.8%\u00a0OBI, 15.5%\u00a0IV), COVID-19 (2.7%, 1.9%), and upper respiratory tract infection (1.5% both arms).\u00a0The most common\u00a0grade \u22653\u00a0hematologic laboratory abnormalities were neutropenia (84.7% OBI, 74.3% IV), thrombocytopenia (26.1%, 23%), and\u00a0anemia\u00a0(17.6%, 19.5%).<\/p>\n

In Japan, Sarclisa IV is currently approved across five indications, including in combination with VRd in NDMM, as well as four different treatment regimens in R\/R MM (in combination with Pd, in combination with carfilzomib and dexamethasone (Kd), in combination with dexamethasone alone, or as a monotherapy). Sarclisa SC administered via both the CirCLIQ OBI and manual injection was approved in the EU for the treatment of MM patients across all currently approved indications and combinations for Sarclisa IV formulation in June 2026. An application for Sarclisa SC administered via both OBI and manual injection is currently under review in the US.<\/p>\n

About the IRAKLIA study\u00a0<\/p>\n

IRAKLIA\u00a0(clinical study identifier:\u00a0NCT05405166<\/a>)\u00a0was\u00a0a randomized, open-label, pivotal phase 3 study evaluating the non-inferiority of\u00a0Sarclisa administered at a fixed dose SC via\u00a0OBI\u00a0versus weight-based dosed\u00a0Sarclisa IV\u00a0in combination with\u00a0Pd\u00a0in adult patients with R\/R MM who have received at least one prior line of therapy. The co-primary outcomes assessed were ORR, defined as the proportion of patients with stringent complete response (CR), CR, very good partial response, and partial response according to the 2016 International Myeloma Working Group criteria assessed by Independent Review Committee,\u00a0and observed\u00a0Sarclisa mean concentration before dosing\u00a0(Ctrough)\u00a0at steady state (pre-dose at\u00a0cycle 6, dose 1 [C6D1]), defined as\u00a0observed\u00a0Sarclisa\u00a0plasma concentrations.<\/p>\n

About Enable\u00a0Injections\u00a0<\/p>\n

Cincinnati-based Enable Injections is a global healthcare innovation company committed to improving the patient treatment experience through the development and manufacturing of the enFuse\u00ae On-Body Delivery System. An innovative wearable technology, the enFuse system is designed to deliver large volumes of pharmaceutical and biologic therapeutics via subcutaneous administration, with the aim of improving convenience, supporting superior outcomes, and advancing healthcare system economics. For more information, visit www.enableinjections.com<\/a>.<\/p>\n

About Sarclisa<\/p>\n

Sarclisa (isatuximab) has been approved in almost 60 countries across four indications for certain patients with NDMM and R\/R MM. Sarclisa-based regimens have been prescribed to treat more than 70,000 patients worldwide.<\/p>\n

Sarclisa SC is approved in the EU and the UK in combination with approved standard-of-care regimens for the treatment of patients with MM across all currently approved indications for Sarclisa IV in these countries. It is the first anticancer treatment to be administered through an OBI, and the only anti-CD38 monoclonal antibody available in MM to offer the flexibility of both SC OBI and manual injection administration.<\/p>\n

Sarclisa SC is approved in Japan in combination with VRd, for the treatment of adult patients with NDMM, as well as Pd and Kd for the treatment of patients with R\/R MM.<\/p>\n

At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need.<\/p>\n

For more information on Sarclisa clinical studies, please visit\u00a0www.clinicaltrials.gov<\/a>.<\/p>\n

About\u00a0Sanofi<\/p>\n

Sanofi is an R&D driven, AI-powered biopharma company committed to improving people\u2019s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more.\u202fOur team is guided by one purpose: we chase the miracles of science to improve people\u2019s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY<\/p>\n

Media Relations<\/p>\n

Sandrine\u00a0Guendoul\u00a0| +33 6 25 09 14 25 |\u00a0[email\u00a0protected]<\/a><\/p>\n

Evan Berland\u00a0| +1 215 432 0234 |\u00a0[email\u00a0protected]<\/a><\/p>\n

L\u00e9o Le Bourhis\u00a0| +33 6 75 06 43 81 |\u00a0[email\u00a0protected]<\/a><\/p>\n

Victor Rouault\u00a0| +1 617 356 4751 |\u00a0[email\u00a0protected]<\/a><\/p>\n

Timothy Gilbert\u00a0| +1 516 521 2929 |\u00a0[email\u00a0protected]<\/a><\/p>\n

L\u00e9a Ubaldi\u00a0| +33 6 30 19 66 46 |\u00a0[email\u00a0protected]<\/a><\/p>\n

Ekaterina\u00a0Pesheva\u00a0| +1 410 926 6780 |\u202f[email\u00a0protected]<\/a><\/p>\n

Investor Relations<\/p>\n

Thomas Kudsk Larsen\u00a0|+44 7545 513 693 |\u00a0[email\u00a0protected]<\/a><\/p>\n

Aliz\u00e9 Kaisserian\u00a0| +33 6 47 04 12 11 |\u00a0[email\u00a0protected]<\/a><\/p>\n

Keita Browne\u00a0| +1 781 249 1766 |\u00a0[email\u00a0protected]<\/a><\/p>\n

Nathalie Pham\u00a0| +33 7 85 93 30 17 |\u00a0[email\u00a0protected]<\/a><\/p>\n

Nina\u00a0Goworek\u00a0|\u00a0+1 908 569 7086\u00a0|\u00a0[email\u00a0protected]<\/a><\/p>\n

Thibaud Ch\u00e2telet\u00a0| +33 6 80 80 89 90 |\u00a0[email\u00a0protected]<\/a><\/p>\n

Yun\u00a0Li\u00a0| +33 6 84 00 90 72 |\u00a0[email\u00a0protected]<\/a><\/p>\n

Sanofi forward-looking statements\u00a0<\/p>\n

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions regarding the marketing and other potential of the product; regarding potential future events and revenues from the product. Words such as “expect,\u201d “anticipate,\u201d “believe,\u201d “intend,\u201d “estimate,\u201d “plan,\u201d “can,\u201d “contemplate,\u201d “could,\u201d “is designed to,\u201d “may,\u201d “might,\u201d “potential,\u201d “objective,\u201d “attempt,” “target,\u201d “project,\u201d “strategy,” “strive,” “desire,” “predict,\u201d “forecast,\u201d “ambition,\u201d “guideline,\u201d “seek,” “should,\u201d “will,\u201d “goal,” or the negative of these and similar expressions are intended to identify forward-looking statements. Although Sanofi\u2019s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks, uncertainties and assumptions include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful; authorities\u2019 decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation\u201d pricing for State Medicaid programs; the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues; competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors\u201d and “Cautionary Statement Regarding Forward-Looking Statements\u201d in Sanofi\u2019s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein.<\/p>\n

All trademarks mentioned in this press release are the property of the Sanofi group\u00a0except for\u00a0enFuse\u00a0and\u00a0CirCLIQ.<\/p>\n

Attachment<\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"Sanofi\u2019s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma Approval based on multiple studies, including…\n","protected":false},"author":2,"featured_media":38491,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12983],"tags":[23122,3048,26730,689,558,26731,26732,14637,1642,3687,13012,19218,14259,23121,2508],"class_list":["post-38490","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sanofi","tag-approved","tag-for","tag-formulation","tag-in","tag-japan","tag-multiple","tag-myeloma","tag-patients","tag-press","tag-release","tag-sanofi","tag-sanofis","tag-sarclisa","tag-subcutaneous","tag-with"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/38490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/comments?post=38490"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/38490\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media\/38491"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media?parent=38490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/categories?post=38490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/tags?post=38490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}